TRexBio, Inc. (Ticker: TRXB US) is an American clinical-stage biotechnology company focused on tissue regulatory T-cell (Treg) biology and the development of immunoregulatory medicines for autoimmune and inflammatory diseases. The company’s Deep Biology platform is designed to identify drivers of immune dysregulation and inform drug discovery and translational development across its wholly owned pipeline and pharmaceutical collaborations. TRexBio is headquartered in South San Francisco, California.

TRexBio is expected to list on Nasdaq on October 9, 2026, following pricing on October 8. The company plans to offer approximately 8.3 million primary shares at $14.00-$16.00 per share, raising approximately $125 million at the midpoint of the proposed range. The offering is 100% primary. J.P. Morgan, Evercore, Cantor and Stifel are serving as bookrunners, with J.P. Morgan acting as stabilization agent and bill-and-deliver bank.